论文部分内容阅读
目的观察厄洛替尼(特罗凯)单药治疗晚期肺癌的疗效及不良反应。方法 36例晚期非小细胞肺癌一线化疗失败患者口服厄洛替尼150mg/d至肿瘤进展或出现不可耐受的不良反应,评价其近期疗效、不良反应及生活质量、无进展生存期及总生存期。结果 36例患者中PR 8例(22.22%),SD 15例(41.66%),PD 13例(36.11%),有效率(CR+PR)为22.22%;疾病控制率(CR+PR+SD)为72.22%。肿瘤进展时间为2～11个月,中位无进展生存期为5.9个月;中位生存期为11.6个月。主要的不良反应为皮疹、皮肤瘙痒、恶心、腹泻,多为Ⅰ～Ⅱ度,对症处理后可缓解。结论厄洛替尼单药二线治疗非小细胞肺癌疗效好、不良反应轻。
Objective To observe the efficacy and adverse reactions of erlotinib (Tarceva) monotherapy in the treatment of advanced lung cancer. Methods 36 cases of advanced non-small cell lung cancer patients with first-line chemotherapy failed oral erlotinib 150mg / d to the progress of the tumor or intolerable adverse reactions to evaluate the short-term efficacy, adverse reactions and quality of life, progression-free survival and overall survival period. Results Among the 36 patients, 8 (22.22%) were PR, 15 (41.66%) were SD, 13 (36.11%) were PD, and the effective rate was 22.22% (CR + PR) Is 72.22%. Tumor progression was 2 to 11 months, median progression-free survival was 5.9 months, and median survival was 11.6 months. The main adverse reactions were skin rashes, pruritus, nausea and diarrhea. Most of them were grade Ⅰ ~ Ⅱ degrees, which were relieved after symptomatic treatment. Conclusion Erlotinib monotherapy second-line treatment of non-small cell lung cancer with good efficacy and mild side effects.